ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Buy” from Brokerages


Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been assigned a consensus rating of “Buy” from the eight research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $90.67.

Several equities analysts recently issued reports on the stock. UBS Group assumed coverage on shares of ALX Oncology in a research note on Tuesday, April 6th. They set a “buy” rating and a $96.00 price objective on the stock. Zacks Investment Research raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, May 20th. Finally, Credit Suisse Group assumed coverage on shares of ALX Oncology in a research note on Wednesday, May 5th. They set an “outperform” rating and a $98.00 price target on the stock.

Shares of ALXO opened at $59.29 on Friday. The stock has a market capitalization of $2.39 billion and a P/E ratio of -10.55. The firm’s 50 day moving average price is $59.09. ALX Oncology has a 1 year low of $28.01 and a 1 year high of $117.45.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Sunday, May 16th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. On average, analysts forecast that ALX Oncology will post -1.73 earnings per share for the current year.

In other news, CEO Jaume Pons sold 16,700 shares of the stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $68.49, for a total value of $1,143,783.00. Following the completion of the sale, the chief executive officer now owns 568,046 shares of the company’s stock, valued at $38,905,470.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sophia Randolph sold 7,387 shares of the stock in a transaction on Monday, April 12th. The stock was sold at an average price of $59.43, for a total transaction of $439,009.41. Following the completion of the sale, the insider now directly owns 198,234 shares of the company’s stock, valued at approximately $11,781,046.62. The disclosure for this sale can be found here. Insiders sold 57,487 shares of company stock valued at $3,475,570 in the last three months. Company insiders own 58.20% of the company’s stock.

(Ad)

Picking the right “investment of the decade” can transform your life…

Today, the Wall Street legend who picked the last “investment of the decade”… months (even years) before his peers… will finally reveal his new #1 pick for the 2020s.

It’s not 5G, artificial intelligence, EVs, or clean energy. The answer will surprise you.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in ALX Oncology during the 1st quarter valued at $49,000. Penserra Capital Management LLC acquired a new stake in ALX Oncology during the 4th quarter valued at $73,000. Pacer Advisors Inc. grew its holdings in ALX Oncology by 126.5% during the 1st quarter. Pacer Advisors Inc. now owns 1,010 shares of the company’s stock valued at $74,000 after purchasing an additional 564 shares in the last quarter. First Mercantile Trust Co. grew its holdings in ALX Oncology by 101.5% during the 4th quarter. First Mercantile Trust Co. now owns 1,209 shares of the company’s stock valued at $104,000 after purchasing an additional 609 shares in the last quarter. Finally, E Fund Management Co. Ltd. acquired a new stake in ALX Oncology during the 1st quarter valued at $133,000. 83.28% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin’s lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer.

Recommended Story: The basics of gap trading strategies

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What is Blockchain?

7 Things You Need To Know About Cryptocurrency

The Cryptocurrency Market Is About To Boil Over

The cryptocurrency was quiet for years, but it’s starting to boil over once again. With the price of Bitcoin up 550%, it certainly seems like the sky is the limit.

Whether or not you choose to trade Bitcoin or any other cryptocurrency, it is important to understand what it is and the trends driving it.

The bottom line, however, is that the world’s money is flowing onto the blockchain, and the use of cryptocurrency is growing at an exponential rate.

View the “7 Things You Need To Know About Cryptocurrency”.



Read More:ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Buy” from Brokerages

Leave a Reply

Your email address will not be published. Required fields are marked *